Total FIT scores
| Consensus item | Total | |
| Round 1 | Round 2 | |
| Drug development | ||
| Simplify and standardise clinical trial outcome measures, including steroid-sparing as an outcome. | 7.28 | 7.67 |
| Increase participant representativeness in clinical trials (e.g., minority, paediatric and cutaneous lupus erythematosus). | 6.67 | 6.56 |
| Propel quality of life-driven studies (e.g., fatigue). | 6.39 | 6.56 |
| Develop data sharing approaches related to biomarkers, clinical data and lab samples. | 6.00 | 6.06 |
| Clinical care | ||
| Define the lupus spectrum. | 6.94 | 7.44 |
| Identify and support development of adherence strategies that work for lupus and communicate them to patients and providers. | 7.17 | 7.22 |
| Drive clinical and lab-based measures for individualised treatments. | 6.06 | 5.89 |
| Perform longitudinal studies of prognostic and diagnostic biomarkers. | 6.17 | 5.50 |
| Access to care | ||
| Leverage social media. | 7.94 | 7.78 |
| Explore broader partnering. | 6.71 | 6.89 |
| Provide payor education and establish alignment. | 6.35 | 6.44 |
| Develop standardised and specialised, expert-driven care pathways. | 6.28 | 6.44 |
| Develop evidence base for interventions, including standardised endpoints/outcomes. | 6.36 | 6.00 |
| Drive telehealth advances and reimbursement, and build on current infrastructures. | 6.22 | 6.00 |
| Build the case for World Health Organization (WHO) prioritisation. | 5.52 | 5.11 |
The solutions are listed in order of highest to lowest Round 2 FIT score within each pillar.
FIT, feasibility, impact and timeline for implementation.